Abdulraheem Yacoub MD

Myeloproliferative Disorder Hematology-Oncology

Assistant Professor, Internal Medicine, University Kansas School of Medicine

2330 Shawnee Mission PkwySte 210Westwood, KS 66205
Phone+1 913-588-6029
Fax+1 913-588-3867

Dr. Yacoub is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Yacoub's full profile Already have an account?

Summary

Dr. Abdulraheem Yacoub is a hematologist based in Westwood, KS, specializing in Myeloid malignancies including myeloproliferative disorders, MDS and AML and hematologic disorders. He completed his fellowship in Hematology and Medical Oncology at the University of Arkansas for Medical Sciences from 2008 to 2011 and his residency in Internal Medicine at SSM Health/Saint Louis University School of Medicine from 2005 to 2008. Dr. Yacoub's expertise includes myeloproliferative neoplasms, CML, MDS, AML and diagnostic and molecular hematology.

Education & Training

University of Arkansas for Medical SciencesFellowship, Hematology and Medical Oncology, 2008 - 2011
SSM Health/Saint Louis University School of MedicineResidency, Internal Medicine, 2005 - 2008
University of Jordan Faculty of MedicineClass of 2003

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

KS State Medical License 2010 - 2027
MO State Medical License 2021 - 2027
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2014, 2016-2017
CMS Meaningful Use Stage 1 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2014, 2016-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017

Clinical Trials

Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2014 Jan 15
ACTIVE_NOT_RECRUITING
PHASE3
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
COMPLETED
PHASE2
Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox. Start of enrollment: 2014 Sep 11
TERMINATED
PHASE2

Publications & Presentations

PubMed

Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EX...
Brandi N Reeves, Firas El Chaer, Lynda Foltz, Tsewang Tashi, Ghaith Abu-Zeinah
Lancet Regional Health. Americas. 2026-09-01
Long term outcomes of idasanutlin therapy in hydroxyurea-refractory polycythemia vera patients.
Megan Metzger, Julian A Waksal, Jayanshu Jain, Natalia Rosas, Margherita Maffioli
Leukemia & Lymphoma. 2026-08-01
Risk of Thromboembolic Events in Patients With Polycythemia Vera: A Real-World Observational Study.
Andrew T Kuykendall, Arturo Molina, Nancy Reaven, Susan Funk, Pedro Oyuela
Clinical Lymphoma, Myeloma & Leukemia. 2026-08-01

Abstracts/Posters

Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis
Abdulraheem Yacoub, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Persistent Leukocytosis in Polycythemia Vera Is Associated with Disease Evolution but Not Thrombosis: An Analysis from a 520-Patient Retrospective Multi-Center Database
Abdulraheem Yacoub, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Identifying Cytokine Biomarkers of Response to Pegylated-Interferon Therapy in Polycythemia Vera and Essential Thrombocythemia: Correlative Analysis from the MPN-RC 11...
Abdulraheem Yacoub, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Set...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
MPN Tumor Board: Application of Novel Agents for the Treatment of Polycythemia Vera and Myelofibrosis
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018